The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 23)
Research Grant, 2017
Assessing the accumulation of tau (protein associated with dementia) and alpha-synuclein (sticky protein associated with Parkinson's) in the living human brain is crucial to better understanding Progressive Supranuclear Palsy (movement disorder that causes impaired balance and vision; PSP), Parkinson's disease (PD) and related neurodegenerative disorders, in addition to aiding in ...
Researchers: Neil Vasdev, PhD
Computational Science 2017, 2017
To test this hypothesis, we will employ recent discoveries in computer science, PD biomarker research and standardized sets of PD data. First, we will develop machine-learning techniques to analyze multimodal data from people with and without Parkinson's. Results will help identify whether someone does or does not have PD, and they will be grouped accordingly. Second, we will confirm ...
Researchers: Wasim Q. Malik, PhD
Improved Biomarkers and Clinical Outcome Measures, 2015
Current methods to evaluate motor impairments in Parkinson's disease rely on subjective examinations. Our team seeks to develop an objective assessment of motor deficits by monitoring natural interactions with a keyboard (on a computer or smart device). This approach provides a window to how the brain behaves during typical daily use of these devices (e.g. writin...
Researchers: Martha L. Gray, PhD
Target Validation, 2014
Individuals with Parkinson's disease (PD) are more likely to develop melanoma. Conversely, melanoma patients are at higher risk of developing PD. This bidirectional link suggests a shared genetic basis for these two seemingly distinct conditions.
In collaboration with melanoma researchers, this study seeks to explore a role of a melanoma-related gene ...
Researchers: Xiqun Chen, MD, PhD
Therapeutic Pipeline Program, 2013
Developing Disease-Modifying Therapies to Treat Parkinsons's Disease by Enhancing the Clearance of Alpha Synuclein
This proposal seeks to develop a novel therapy that can slow the progression of Parkinson's disease (PD) by optimizing chemical compounds that can decrease levels of alpha synuclein in the brain.
Neurodegenerative diseases are characterized by the accumulation in cells of damaged and misfolded proteins that form toxic aggregates, ultimately leading to cell ...